Press Releases

January 7, 2018 — Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Click here to read the full release.

December 11, 2017 — Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials

Click here to read the full release.

December 1, 2017 — Impact Biomedicines Closes First Tranche of Oberland Capital Financing Following FDA Meeting

Click here to read the full release.

November 27, 2017 — Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting

Click here to read the full release.

October 26, 2017 — Impact Biomedicines Closes $90 Million Financing with Oberland Capital to Fund Fedratinib Program Advancement

Click here to read the full release.

October 13, 2017 — Startup Impact Biomedicines Raises $22M to Bring Fedratinib to Myelofibrosis Patients

Click here to read the full release.

Scroll To Top

Featured News: ASH Annual Meeting 2017

Learn about the data and development program we’ll be discussing at this year’s American Society of Hematology Annual Meeting.

“At Impact Biomedicines, we are pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers.” – John Hood, CEO, Impact

Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials

Click here to read our news release and here for our infographic.

18,000 people in the U.S. are living with myelofibrosis, while polycythemia vera affects 100,000 people

Click here to learn more about this difficult to treat condition.

The future is in sight again

Click here to learn about the chronology and status of our development program.

Follow Impact on Twitter via and keep up to date with ASH Annual Meeting news and updates by using the hashtag .

Scroll To Top

Presentations and Publications

Effect of treatment with a JAK2-selective inhibitor, Fedratinib, on bone marrow fibrosis in patients with myelofibrosis

Click here to read the full article.

Safety and efficacy of Fedratinib in patients with Primary or Secondary Myelofibrosis

Click here to view the article at the Jama Network.

Janus kinase-2 inhibitor Fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open label, non-randomised, phase 2, multicentre study

Click here to view the article at The Lancet.

Treatment of rats with the JAK-2 inhibitor Fedratinib does not lead to experimental Wernicke’s Encephalopathy

Click here to read the full article. Click here to view the article at Science Direct.

Scroll To Top

Press Releases

January 7, 2018 — Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Click here to read the full release.

December 11, 2017 — Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials

Click here to read the full release.

December 1, 2017 — Impact Biomedicines Closes First Tranche of Oberland Capital Financing Following FDA Meeting

Click here to read the full release.

November 27, 2017 — Impact Biomedicines to Present Retrospective Data on Fedratinib at the 2017 ASH Annual Meeting

Click here to read the full release.

October 26, 2017 — Impact Biomedicines Closes $90 Million Financing with Oberland Capital to Fund Fedratinib Program Advancement

Click here to read the full release.

October 13, 2017 — Startup Impact Biomedicines Raises $22M to Bring Fedratinib to Myelofibrosis Patients

Click here to read the full release.

Scroll To Top

Featured News: ASH Annual Meeting 2017

Learn about the data and development program we’ll be discussing at this year’s American Society of Hematology Annual Meeting.

“At Impact Biomedicines, we are pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers.” – John Hood, CEO, Impact

Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials

Click here to read our news release and here for our infographic.

18,000 people in the U.S. are living with myelofibrosis, while polycythemia vera affects 100,000 people

Click here to learn more about this difficult to treat condition.

The future is in sight again

Click here to learn about the chronology and status of our development program.

Follow Impact on Twitter via and keep up to date with ASH Annual Meeting news and updates by using the hashtag .

Scroll To Top

Presentations and Publications

Effect of treatment with a JAK2-selective inhibitor, Fedratinib, on bone marrow fibrosis in patients with myelofibrosis

Click here to read the full article.

Safety and efficacy of Fedratinib in patients with Primary or Secondary Myelofibrosis

Click here to view the article at the Jama Network.

Janus kinase-2 inhibitor Fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open label, non-randomised, phase 2, multicentre study

Click here to view the article at The Lancet.

Treatment of rats with the JAK-2 inhibitor Fedratinib does not lead to experimental Wernicke’s Encephalopathy

Click here to read the full article. Click here to view the article at Science Direct.

Scroll To Top